Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed

Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still hold...